<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131907</url>
  </required_header>
  <id_info>
    <org_study_id>PR1087</org_study_id>
    <nct_id>NCT04131907</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH</brief_title>
  <acronym>PINNACLE</acronym>
  <official_title>A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urotronic Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinLogix. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Urotronic Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the
      safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic
      hyperplasia (BPH)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in subjects' International Prostate Symptom Score (IPSS) from pre-procedure to 12-months. The IPSS can be interpreted as follows: 0-7 mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Device Related Serious Complications</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of major device related serious complications</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Optilume™ BPH Catheter System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The Sham Device is a 21 Fr Optilume BPH, Prostatic Pre-dilation Catheter within the sheath.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacokinetics Optilume Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single arm of 15 non-randomized subjects will be treated in the pharmacokinetics (PK) arm. These subjects will be treated with the Optilume BPH Catheter System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optilume BPH Catheter System</intervention_name>
    <description>The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.</description>
    <arm_group_label>Optilume™ BPH Catheter System</arm_group_label>
    <arm_group_label>Pharmacokinetics Optilume Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optilume Sham Device</intervention_name>
    <description>21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)</description>
    <arm_group_label>Sham Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male subject 50-80 years of age who has symptomatic BPH

          2. International Prostate Symptom Score (IPSS) ≥ 13

          3. Peak urinary flow rate (Qmax) ≥ 5 ml/sec and ≤ 12 ml/sec (with minimum voided volume
             of ≥ 150 ml)

          4. Prostate volume 20 to 80 gm as determined by transrectal ultrasound (TRUS)

          5. Prostatic urethral length ≥ 32 mm as determined by TRUS

          6. History of inadequate response, contraindication, or refusal of BPH medical therapy

          7. Able to complete the study protocol in the opinion of the investigator

        Exclusion Criteria:

          1. Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with all the
             follow-up requirements

          2. Unwilling to abstain or use protected sex for the first 30 days post treatment

          3. Unwilling to abstain from sexual intercourse or use a highly effective contraceptive
             for at least 6 months post-procedure

          4. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate

          5. Any prior minimally invasive intervention (e.g. TUNA, Balloon, Microwave, Rezūm,
             UroLift) or surgical intervention of the prostate

          6. Prostate specific antigen (PSA) ≥ 10 ng/ml unless prostate cancer is ruled out by
             biopsy

          7. Confirmed or suspected malignancy of prostate or bladder

          8. Active or history of epididymitis within the past 3 months

          9. Previous pelvic irradiation or pelvic trauma surgery

         10. Active urinary tract infection (UTI) confirmed by culture

         11. Bacterial prostatitis within the last 12 months

         12. Non-bacterial prostatitis within the last 5 years

         13. Visible or invisible hematuria (&gt; 4 Red Blood Cells (RBCs) per high power field) on 2
             separate urine specimens within the last 3 months

         14. Neurogenic bladder or sphincter abnormalities or neurological disorders that might
             affect bladder or sphincter function

         15. History of urinary incontinence

         16. Previous or current diagnosis of urethral strictures, bladder neck contracture or
             detrusor muscle spasms

         17. Previous rectal surgery, other than hemorrhoidectomy

         18. Use of antihistamines, anticonvulsants or antispasmodics within 1 week prior to
             treatment unless there is documented evidence of stable dosing for last 6 months (no
             dose changes)

         19. Use of alpha blockers, antidepressants with adrenergic effects (i.e. duloxetine,
             imipramine and amitriptyline), long-acting anticholinergics (LAAC) for chronic
             obstructive pulmonary disease (COPD), or androgens within 2 weeks prior to baseline
             assessment

         20. Use of Luteinizing Hormone-Releasing Hormone (LHRH) analogs within 12 months prior to
             baseline assessment

         21. Use of Type II 5-alpha reductase inhibitor [e.g. finasteride (Proscar, Propecia)]
             within 3 months of baseline assessment

         22. Use of 5-alpha reductase inhibitor [e.g. dutasteride (Avodart)] within 6 months of
             baseline assessment

         23. Use of estrogen, drug-producing androgen suppression or anabolic steroids unless there
             is documented evidence of stable dosing for last 3 months (no dose changes)

         24. Use of daily dose PD5 inhibitor (e.g. Cialis) within the last 4 weeks

         25. Use of warfarin or novel oral anti-coagulants [e.g., apixaban (Eliquis), fondaparinux
             (Arixtra), rivaroxaban (Xarelto) or edoxaban (Savaysa)], unless the medication is
             safely discontinued prior to the procedure and is not planned to be restarted for at
             least 5 days post-procedure

         26. Use of anti-platelet medications (e.g., clopidogrel, aspirin) within the last 10 days
             or planned use within 5 days post-procedure

         27. History of hypersensitivity reactions to paclitaxel, on medication that may have
             negative interaction with paclitaxel, presence of solid tumor with a baseline
             neutrophil count of &lt;1500 cells/mm3 or AIDS-related Kaposi's sarcoma with baseline
             neutrophil count of &lt;1000 cells/mm3

         28. Incidence of spontaneous urinary retention within 6 months prior to baseline
             assessment

         29. Current post-void residual volume &gt; 300 ml or catheter dependent bladder drainage

         30. Known poor detrusor muscle function (e.g. Qmax &lt; 5 ml/sec)

         31. Current bladder or prostatic urethral stones

         32. Biopsy of prostate within 40 days prior to procedure

         33. History of cancer in non-genitourinary system which is not considered in complete
             remission (except basal cell or squamous cell carcinoma of the skin). A potential
             participant is considered in complete remission if there has been no evidence of
             cancer within five years

         34. Current uncontrolled diabetes (i.e. hemoglobin A1c ≥ 8%)

         35. History of clinically significant comorbidities or presence of unstable conditions
             [e.g. cardiovascular, lung, renal (serum creatinine &gt; 2.0 mg/dl), hepatic, bleeding
             disorders or metabolic impairment] that may confound the results of the study or have
             a risk to subject per investigator's opinion

         36. Any cognitive disorder that interferes with or precludes direct and accurate
             communication with the study investigator regarding the study or affects the ability
             to complete the study quality of life questionnaires

         37. Life expectancy &lt; 10 years

         38. Anatomy (e.g. presence of false passage or size of meatus) is not suitable for
             treatment in this study

         39. Significant median lobe component [e.g. intravesical prostatic protrusion (IPP) &gt; 1
             cm]

         40. Device that corresponds with the subject's prostate size is not available

         41. Currently enrolled in or plan to enroll in another investigational clinical study for
             any disease except for observational only study

         42. In the opinion of the investigator, it is not in the subject's best interest to
             participate in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Moland</last_name>
    <phone>833-400-4032</phone>
    <email>molandj@urotronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Polly Sizemore</last_name>
    <phone>215-855-9054</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Institute</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Urologic Care</name>
      <address>
        <city>Lake Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheldon Freedman MD, Ltd</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Urology</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western New York Urology Associates</name>
      <address>
        <city>Cheektowaga</city>
        <state>New York</state>
        <zip>14225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research Practice, PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of NC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Austin Urology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rio Grande Urology</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

